Vera Therapeutics (VERA) is back in focus after the FDA granted priority review to its lead drug candidate, atacicept, following positive Phase 3 IgA nephropathy data and company updates on funding and launch readiness.

Despite the FDA priority review and Phase 3 success for atacicept, Vera Therapeutics’ recent share price returns have cooled, with a 30 day share price return decline of 5.71% and a year to date share price return decline of 16.10%. However, the 90 day share price return of 23.61% and a three year total shareholder return that is well over 4x still point to strong longer term momentum.

If progress at Vera has you looking more broadly at biotech opportunities tied to AI and data, it could be a good time to scan 27 healthcare AI stocks as a fresh set of ideas.

With Vera still loss making and the stock trading at a large intrinsic discount, investors are left with a simple question: is this IgAN leader quietly undervalued, or is the market already pricing in the next leg of growth?

Preferred Price to Book of 4.8x: Is it justified?

Vera Therapeutics last closed at $40.79 and the stock is trading on a P/B of 4.8x, which screens as expensive against both the biotech industry and direct peers.

P/B compares a company’s market value to its net assets. It is often used for early stage or loss making biotechs where traditional earnings metrics do not apply. A higher P/B usually signals the market is placing a premium on the pipeline, future cash flow potential or balance sheet strength relative to book value.

For Vera, that 4.8x P/B sits above the US biotech industry average of 2.7x and also above the peer average of 3.4x, so the market is assigning a clear premium compared with similar names. At the same time, Simply Wall St’s DCF model suggests the shares are trading at an 81% discount to its estimate of future cash flow value of $215.22, which points to a different signal to what the P/B comparison alone implies.

Result: Price to Book of 4.8x (OVERVALUED)

However, you still need to weigh real swing factors such as ongoing losses, with net income at a loss of $299.615 million, and the risk of clinical or regulatory setbacks.

Another View: DCF Says The Market May Be Too Harsh

If you put the P/B to one side and look at our DCF model, the picture changes sharply. Vera trades at $40.79 while the SWS DCF model points to a future cash flow value of $215.22, suggesting the shares are 81% below that estimate. Is the market over discounting the clinical and funding risks here?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Vera Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 46 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If the mix of promise and caution in this story feels finely balanced, consider reviewing the numbers yourself and weighing both sides by looking at 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Vera has sharpened your focus, do not stop here, the market is full of other opportunities that could fit your style and risk comfort.

• Target quality at a discount by checking our list of 46 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect their potential.
• Prioritise resilience and sleep better at night by reviewing 74 resilient stocks with low risk scores, focused on companies with more stable risk profiles.
• Get ahead of the crowd by scanning our screener containing 24 high quality undiscovered gems that highlight under followed businesses with strong underlying metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.